ALSO NOTED: Jubilant buys generic company; NitroMed marketing BiDil; Aurobindo gets FDA nod for AIDS drug; and much more

> India's Jubilant Organosys has inked a deal to buy the U.S. generic drug company Trinity Laboratories and its wholly owned subsidiary Trigen Laboratories for $12.25 million. Story

> NitroMed has begun marketing BiDil for heart failure in black patients. Release

> India's Aurobindo Pharma has received tentative FDA approval for the generic AIDS drug efavirenz. Story

and finally...The FDA says that contrary to popular belief, green tea probably has little ability to prevent any kind of cancer. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.